Tecan Group AG
SIX:TECN

Watchlist Manager
Tecan Group AG Logo
Tecan Group AG
SIX:TECN
Watchlist
Price: 203 CHF 2.78% Market Closed
Market Cap: 2.6B CHF
Have any thoughts about
Tecan Group AG?
Write Note

Tecan Group AG
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tecan Group AG
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Tecan Group AG
SIX:TECN
Accrued Liabilities
CHf71.6m
CAGR 3-Years
0%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Accrued Liabilities
CHf49.7m
CAGR 3-Years
7%
CAGR 5-Years
22%
CAGR 10-Years
20%
Siegfried Holding AG
SIX:SFZN
Accrued Liabilities
CHf102.3m
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Accrued Liabilities
€14.9m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Accrued Liabilities
CHf6.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tecan Group AG
Glance View

Market Cap
2.6B CHF
Industry
Life Sciences Tools & Services

Nestled in the heart of Switzerland lies Tecan Group AG, a company that has been quietly revolutionizing the laboratory world. Founded in 1980, Tecan has transformed itself from a small enterprise into a powerhouse in the life sciences and diagnostics sectors. The company's journey is one of precision and innovation, as it specializes in the development, production, and distribution of sophisticated laboratory instruments and solutions. These solutions are not merely products; they are the linchpins of automation that help streamline research, diagnostics, and the pharmaceutical sectors. Tecan's knack for integrating complex biochemical processes into accessible technology has proven critical for laboratories seeking speed and accuracy in processes like sample handling, testing, and data management. Tecan's business model thrives on a multifaceted approach. It sells its high-tech instruments and consumables directly to a diverse client base, including pharmaceutical companies, biotechnology firms, and research institutions. Beyond selling physical products, Tecan also benefits from providing value-added services such as after-sales support and bespoke system adaptations, ensuring that its clients can optimize their workflows. By combining cutting-edge technology with customer-centric service offerings, Tecan ensures recurring revenue streams. Its strategic prowess in securing long-term partnerships with leading institutions further cements its stance as not just a vendor, but a reliable partner in scientific discovery and healthcare advancement.

TECN Intrinsic Value
351.42 CHF
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Tecan Group AG's Accrued Liabilities?
Accrued Liabilities
71.6m CHF

Based on the financial report for Jun 30, 2024, Tecan Group AG's Accrued Liabilities amounts to 71.6m CHF.

What is Tecan Group AG's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
12%

Over the last year, the Accrued Liabilities growth was -17%.

Back to Top